top of page
final logo w tag

About us

Fastox is a Swiss biotechnology start-up created by seasoned experts in biotech and botulinum neurotoxins.

Millions of treatments with botulinum neurotoxin A (BoNT-A) are performed in both therapeutics and aesthetics every year. However, there are 2 limitations with this very efficient treatment: its onset of action, it indeed takes a few days for the toxin to settle, and, most importantly, its duration, limited to 3 to 4 months. Patients need to come back regularly to get re-treated and, before the re-injection, the symptoms reappearance impacts their quality of life.

Fastox was created for accelerating the onset of botulinum toxin A (hence its name…) by combining it with a fast-acting mini-toxin from a marine shell. While testing this hypothesis, we serendipitously discovered that this mini-toxin could also significantly increase the duration of action of BoNT-A.

After screening approximately 200 molecules with similar activities, we selected our lead product FTP-501, the most potent BoNT-A duration enhancer with a very good safety profile.

FASTOX PRESENTATION VIDEO ON BFM TV

About the event

Fastox is a Remora venture

Remora Biotech SA is a venture portfolio Company based in Lausanne, Switzerland.

Founded by Jean-Marc Le Doussal and Partners in 2010,

Remora Biotech creates, finances and manages early-stage ventures developing innovative biologics in immunology and anti-aging.

remora BIOTECH_edited.webp
Connectwork

Leadership team

JMLD.jpg

Jean-Marc LE DOUSSAL

President

Jean-Marc is a serial entrepreneur in biotech... read more

NH.jpg

Natalene HOEPFFNER

VP marketing & Business Development

Before joining Fastox, Natalene has been with Galderma... read more

MM.jpg

Mickael MACHICOANE

VP Innovation

Mickael manages the research and intellectual property... read more

close up BoNT vials and syringe.jpeg

Board of directors

JMLD.jpg

Jean-Marc LE DOUSSAL

President

Jean-Marc is a serial entrepreneur in biotech... read more

NH.jpg

Natalene HOEPFFNER

VP marketing & Business Development

Before joining Fastox, Natalene has been with Galderma... read more

benoit_chardon.jpg

Benoit CHARDON

Chief Commercial Officer Allurion

Benoît has over 18 years of experience in Medical... read more

Strategic Advisory Board

bENJAMIN-ascher.png

Benjamin Ascher, MD

Plastic surgeon
Paris, France

Founder of the Iéna clinic in Paris... read more

Andre-friedli.jpg

Andre Friedli, MD

Dermatologist
Geneva, Switzerland

One of the top botulinum toxin injectors... read more

Jean-Michel Gracies.png

Jean-Michel Gracies, MD, PhD

Professor of Rehabilitation Medicine

Paris, France

Professor and Chair in the Neurorehabilitation... read more

Mark-nestor.png

Mark Nestor, MD, PhD

Dermatologist
Miami, USA

Director of the Center for Cosmetic... read more

Giampietro Schiavo.png

Giampietro Schiavo, PhD

Professor of Cellular Neuroscience

London, UK

Senior Group Leader at the Cancer Research UK London... read more

Xavier Yon.png

Xavier Yon

Business Executive

Paris, France

Managing Director of XY Consulting... read more

BoNT vials and syringe.jpeg
Technology

Technology

After screening approx. 200 molecules with similar activities, we selected our lead candidate FTP-501, the most potent BoNT-A enhancer with a very good safety profile.

In-house laboratory

Image9.png
remora BIOTECH_edited.webp

Fastox has a fully equipped 200m2 laboratory hosted at Remora Biotech facility in Nantes, France.

The laboratory has access to the Nantes University technical platforms.

Fastox a has dedicated technical team for animal experiments and can use Remora specialists in bioinformatics, animal models, biochemistry and cell biology.

Université_de_Nantes_logo.svg_.png

Pipeline

FTP-501: Fastox lead candidate will be entering clinical stage in 2023.

The graph on the right represents a typical outcome of the DAS (digit abducting score) in rats showing an improvement of the FTP-501 combination with botulinum toxin A compared to the toxin alone. This improvement is consistent across all time points, from peak effect to return to baseline: we gain, on average, at each timepoint, one point on the DAS score (5-point scale).

These results are reproducible across experiments, labs and botulinum toxin doses and brands.

 

Fastox first patent “composition of matter” has been published in 2020: WO2020/254690

GRAPH.jpg

Publication

The Fastox team will be presenting its groundbreaking technology at the Toxins 2022 6th International conference in New Orleans from July 27th to July 30th 2022. The poster will be available during 6 months after the conference in the Toxicon journal.

Botulinum Toxin Type A Duration Enhancement by Mu-Conotoxin CnIIIC.

Botulinum Toxin Type A Duration Enhancement by Mu-Conotoxin CnlllC.

Image10.jpg
Contact Us
bottom of page